PERSONALIZED STARVATION THERAPY FOR CANCER
Disclosed herein are methods of administering an inhibitor of the mevalonate pathway with a diet low in cholesterol or lipids. The methods of the present invention can be used to treat conditions such as cancer.
1 . A method of treating a cancer in a subject in need thereof, the method comprising:
a) administering to the subject a therapeutically effective amount of an inhibitor of a mevalonate pathway; and
b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids.
2 . The method of claim 1 , wherein the diet comprises less than about 200 mg/day of cholesterol.
3 . The method of claim 1 , wherein the inhibitor of the mevalonate pathway is an HMG-CoA reductase inhibitor.
4 . The method of claim 3 , wherein the diet comprises less than about 200 mg/day of cholesterol.
5 . The method of claim 1 , wherein the subject is a human.
6 . (canceled)
7 . The method of claim 1 , wherein the cancer is lung cancer, pancreatic cancer, head and neck cancer, colorectal cancer, renal cancer, breast cancer, a blood cancer, or liver cancer.
8 - 15 . (canceled)
16 . The method of claim 1 , wherein the inhibitor of the mevalonate pathway is a statin.
17 . (canceled)
18 . The method of claim 16 , wherein the statin is atorvastatin or a pharmaceutically acceptable salt thereof, fluvastatin or a pharmaceutically acceptable salt thereof, pravastatin or a pharmaceutically acceptable salt thereof, rosuvastatin or a pharmaceutically acceptable salt thereof, simvastatin or a pharmaceutically acceptable salt thereof, pitavastatin or a pharmaceutically acceptable salt thereof, or lovastatin or a pharmaceutically acceptable salt thereof.
19 . The method of claim 18 , wherein the statin is atorvastatin calcium, fluvastatin sodium, pravastatin sodium, rosuvastatin calcium, simvastatin sodium, pitavastatin calcium, pitavastatin magnesium, or lovastatin sodium.
20 . The method of claim 18 , wherein the therapeutically effective amount of the atorvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day, the therapeutically effective amount of the fluvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day, the therapeutically effective amount of the pravastatin or the pharmaceutically acceptable salt is from about 20 mg/day to about 60 mg/day, the therapeutically effective amount of the rosuvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day, the therapeutically effective amount of the simvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day, the therapeutically effective amount of the pitavastatin or the pharmaceutically acceptable salt is from about 1.5 mg/day to about 4.5 mg/day, or the therapeutically effective amount of the lovastatin or the pharmaceutically acceptable salt is from about 1 mg/day to about 5 mg/day.
21 - 39 . (canceled)
40 . The method of claim 1 , further comprising administering a therapeutically-effective amount of a cholesterol lowering agent.
41 - 43 . (canceled)
44 . The method of claim 1 , further comprising administering a cancer therapy.
45 . The method of claim 44 , wherein the cancer therapy is a chemotherapeutic agent.
46 . The method of claim 44 , wherein the cancer therapy is radiotherapy.
47 . The method of claim 44 , wherein the cancer therapy is an immunotherapy.
48 . The method of claim 1 , wherein the diet is a vegan diet, a vegetarian diet, a plant based diet, or a diet devoid of animal fats.
49 - 91 . (canceled)
92 . The method of claim 40 , wherein the cholesterol lowering agent is a cholesteryl ester transfer protein (CETP) inhibitor, a lecithin-cholesterol acyltransferase (LCAT) inhibitor, a bile acid sequestrant, or a cholesterol absorption inhibitor.
93 - 122 .
123 . The method of claim 1 , wherein the diet comprises less than 15% of total kcal/day in saturated fats.
124 . The method of claim 1 , wherein the diet comprises less than 5% of total kcal/day in trans fats.
125 . The method of claim 1 , wherein the diet comprises less than 15% of total kcal/day in polyunsaturated fats.
126 . The method of claim 1 , wherein the diet comprises less than 5% of total kcal/day in monounsaturated fats.
127 . The method of claim 1 , wherein the diet comprises less than 20 g/day a daily recommended intake value of saturated fat.
128 . (canceled)
129 . The method of claim 1 , wherein the subject consumes a 2000 kcal/day diet.